Heart and Blood Diseases

Diseases and Abnormalities at or Before Birth

All Conditions

Neoplasms

Arteriovenous Malformations

Congenital Abnormalities

Hemangioma

Vascular Malformations

Cardiovascular Abnormalities

Vascular Diseases

Neoplasms, Vascular Tissue

Neoplasms by Histologic Type

All Drugs and Chemicals

Antineoplastic Agents

Reproductive Control Agents

Progesterone

Medroxyprogesterone Acetate

Medroxyprogesterone

Contraceptive Agents

Contraceptives, Oral

Contraceptives, Oral, Hormonal

Contraceptive Agents, Female

Contraceptive Agents, Hormonal

Contraceptive Agents, Male

Antineoplastic Agents, Hormonal

The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.

MedroxyPROGESTERone Injection [Depo-Provera]

Other

A randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation

Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation

Management of Uterine Arteriovenous Malformation- a Comparison of 2 Management Possibilities- Observation vs. Progesterone Treatment/ a Randomized Control Trial

HaEmek Medical Center, Israel

Nervous System Diseases

Epilepsy

Brain Diseases

Central Nervous System Diseases

Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.

dMRI Scan

The purpose of the dMRI-1 data collection study is to establish a database of clinical images and limited medical history information from patients that have previously received a dMRI scan. All data collected will be de-identified. No safety or effectiveness assessments will be completed.

Diffusion MRI-1 Imaging Database

Medtronic Spinal and Biologics

Blood and Lymph Conditions

Immune System Diseases

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, B-Cell

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

All patient who signed the consent form for participation to the study

real world treatment and survival of DLBCL patients in China

Weili Zhao

Pengpeng Xu

Weili Zhao, MD, PhD

Pengpeng Xu, MD, PhD

To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes

DLBCL is a highly common malignant tumor in Asia. The aim of the study is to observe and explore the clinical information on DLBCL patients with different genetic subtypes and to analyze the clinical characteristics and prognosis of different molecular subtypes of DLBCL. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors. The results can guide future precision therapy for DLBCL.

Real-World Study of DLBCL With Different Genetic Subtypes

A Real-World Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Different Genetic Subtypes

Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death from any cause, whichever occurs first.

Objective Remission Rate (ORR) is defined as the proportion of patients with complete remission (CR) and partial remission (PR)

Complete Remission Rate (CRR) is defined as the proportion of patients with CR

Overall survival (OS) refers to the time from receiving the first dose to death from any cause

Duration Of Remission (DOR) refers to the time from the first CR or PR to the time of the first PD or death from any cause

Time to remission (TTR) refers to the time from recruitment to the time first CR or PR

Ruijin Hospital

Principal Investigator, Clinical Professor

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Immunomodulating Agents

Phase 1b will determine maximal tolerated dose and/or recommended phase 2 dose of D-1553 in combination with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.

Phase 2 will evaluate the efficacy and safety of D-1553 combined with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.

D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

D-1553

Bingxin Xue

Shun Lu

Yiping Zhang

This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Subject incidence of Dose-limiting toxicities (DLT)

Number of subjects participants with adverse events

Overall Response Rate (ORR, Complete Response \[CR\] + Partial Response \[PR\])

InventisBio Co., Ltd

Digestive System Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Panitumumab

50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist

50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1

50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1

No intervention other than routine medical care

This non-interventional retrospective medical record review study will assess the prevalence of KRAS testing and the impact of the KRAS test result on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix in selected European countries over 3 rounds. As the optimal use of Vectibix also requires accurate KRAS mutation testing, this study will also assess data from the laboratory that performed the KRAS test. The study will also monitor changes in the pattern of Vectibix treatment between the different rounds of the study.

The medical record review will be conducted for 3 rounds in months 0, 12, and 24 after the first medical record abstraction. Before the beginning of the study, a sampling list will be created by Amgen by merging lists of oncologists (and their contact information) to be collected from Cegedim, the ESMO, from major cancer centers and oncology clinics in various countries within Europe. In each round of medical record review, potential participating oncologists will be randomly sampled from all identified oncologists. Potential oncologists will be contacted by letter, telephone or email. The oncologists will be introduced to the study, and their eligibility to participate in the study will be assessed using a standardized questionnaire. The number of oncologists sampled per country will be proportional to the number of oncology centers per country. Approximately 50 oncologists will participate in each round of the study. From each eligible participating oncologist, study staff will then obtain approximately 3 or more medical records for patients who have received Vectibix for the treatment of mCRC during the 6-month period prior to the time of contact with the relevant oncologist and are not involved in an experimental clinical trial when treated with Vectibix. A written consent may be obtained from participating patients to access their medical records, depending on local laws. Medical information will be abstracted from the medical records using standardized forms. Such medical information will include the occurrence and timing of treatment with Vectibix and oxaliplatin-containing chemotherapy, diagnosis of mCRC and the occurrence, timing and results of KRAS testing. The oncologist will also be asked to collect information from the pathology laboratory that performed the KRAS mutation test on the patient, using a standardized pathology data extraction form.

Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe

The proportion of patients with mCRC treated with Vectibix only or treated with Vectibix and concurrently treated with oxaliplatin-containing chemotherapy who received a KRAS test to determine tumor KRAS status prior to treatment with Vectibix, and characterize the results of above testing for KRAS testing: proportion that are mutant, wild-type or unknown but tested

The study will obtain data from laboratories that tested KRAS status on mCRC patients who were treated with Vectibix.

Amgen

Symptoms and General Pathology

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Virus Diseases

Papilloma

Communicable Diseases

Respiratory Tract Infections

Papillomavirus Infections

Disease Attributes

Neoplasms, Squamous Cell

Neoplasms, Glandular and Epithelial

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

DNA Virus Infections

Tumor Virus Infections

Genital Diseases

Urogenital Diseases

Recurrent Respiratory Papillomatosis

Antirheumatic Agents

Dermatologic Agents

Anti-Infective Agents

Anti-Inflammatory Agents

Analgesics

Gastrointestinal Agents

Micronutrients

Hematinics

Other Dietary Supplements

Vitamins

Bevacizumab

Methotrexate

Acyclovir

Celecoxib

Isotretinoin

Interferons

Tretinoin

Interferon-alpha

Interferon-alfa-1b

Artemisinins

Artemisinin

Cimetidine

Cidofovir

Indole-3-carbinol

Antimetabolites

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Immunosuppressive Agents

Immunologic Factors

Antiviral Agents

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Cyclooxygenase 2 Inhibitors

Cyclooxygenase Inhibitors

Antacids

Anti-Ulcer Agents

Histamine

Histamine H2 Antagonists

Histamine phosphate

Histamine Antagonists

Neurotransmitter Agents

Cytochrome P-450 Enzyme Inhibitors

Antimalarials

Antiprotozoal Agents

Antiparasitic Agents

Protective Agents

Indole

Folinic Acid

Folate

Vitamin B9

Microdebrider

Cold-steel surgery (forceps)

Removal of lesions via carbon dioxide laser

Carbon dioxide laser

Potassium titanyl phosphate (KTP) laser

Pulsed dye laser

Removal of lesions via radiofrequency ablation

Radiofrequency ablation

Removal of lesions via monopolar suction diathermy

Monopolar suction diathermy

Removal of lesions via plasma coagulation

Plasma coagulation

Adjuvant therapies

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation	NCT05491343	Arteriovenous M...	MedroxyPROGESTE... Other	18 Years - 50 Years	HaEmek Medical Center, Israel
Diffusion MRI-1 Imaging Database	NCT03775694	Epilepsy Tumor Healthy Other	dMRI Scan	-	Medtronic Spinal and Biologics
Real-World Study of DLBCL With Different Genetic Subtypes	NCT06026488	DLBCL - Diffuse... Lymphoma	Other	18 Years -	Ruijin Hospital
Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation	NCT05491343	Arteriovenous M...	MedroxyPROGESTE... Other	18 Years - 50 Years	HaEmek Medical Center, Israel
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer	NCT05492045	NSCLC	D-1553 Other	18 Years -	InventisBio Co., Ltd
Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe	NCT01791361	Metastatic Colo...	Other	18 Years -	Amgen
Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)	NCT03465280	Recurrent Respi... Human Papilloma...	Microdebrider Cold-steel surg... Carbon dioxide ... Potassium titan... Pulsed dye lase... Radiofrequency ... Monopolar sucti... Plasma coagulat... Other Adjuvant therap...	-	Newcastle-upon-Tyne Hospitals NHS Trust
Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors	NCT01074320	Breast Cancer	Other	18 Years -	HealthPartners Institute
Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)	NCT03465280	Recurrent Respi... Human Papilloma...	Microdebrider Cold-steel surg... Carbon dioxide ... Potassium titan... Pulsed dye lase... Radiofrequency ... Monopolar sucti... Plasma coagulat... Other Adjuvant therap...	-	Newcastle-upon-Tyne Hospitals NHS Trust

Spots Global Cancer Trial Database for other

Every month we try and update this database with for other cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for other

Every month we try and update this database with for other cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for other cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.